Funding in, findings out
For any dataset: the NCI award that paid to create it, and the awards that got a published finding out of it afterwards.
TARGET-ALL-P3
Acute Lymphoblastic Leukemia - Phase III
0 awards paid to create it · 30 awards funded work that used it
1. Awards that paid to create this data
2. The dataset
3. Articles that used it (6 of 7)
- Brady et al. · Nature genetics · 2022343 citations
- Mendiratta et al. · Nature communications · 2021187 citations
- Pölönen et al. · Nature · 2024130 citations
- McNeer et al. · Leukemia · 2019121 citations
- Umeda et al. · Blood cancer discovery · 2022105 citations
- Truong et al. · Clinical cancer research : an official journal of the American Association for Cancer Research · 202430 citations
The best connected are shown.
4. Awards those articles were funded by (6 of 30)
- Translating genomic discoveries to improved outcomes for high risk acute leukem… · Charles G Mullighan · FY2017–2026funded 2 of these 7 articles
- Cancer Biology (CBP) · Douglas R. Green, Elizabeth Fox · FY1985–2026funded 3 of these 7 articles
- Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) · Nilsa Del Carmen Ramirez Milan, GREGORY H REAMAN · FY2005–2014funded 2 of these 7 articles
- Childhood Hematological Malignancies Training Program · Charles G Mullighan · FY2019–2026funded 2 of these 7 articles
- COG NCTN Network Group Operations Center · Douglas S. Hawkins, Richard Aplenc · FY2014–2026funded 3 of these 7 articles
- Children's Oncology Group Statistics and Data Center · TODD A ALONZO, Meenakshi Devidas · FY2014–2026funded 3 of these 7 articles
The best connected are shown.
Why one side of this chain is empty
- No repository or reviewer names this dataset's marker paper, so no award can be credited with creating it.
Awards that funded work using this data
7 of 10 traced articles report an NCI award.
| Award | Project | Articles it is credited on | Evidence |
|---|---|---|---|
| R00CA241297 R00FY2020–2022$747k | Characterization of novel subtypes in B progenitor acute lymphoblastic leukemia | API | |
| R01CA216391 R01FY2018–2022$2.8M | Discovery of Somatic Noncoding Variants that Serve as Drivers in Pediatric Cancers | API | |
| R35CA197695 R35FY2017–2026$11.4M | Translating genomic discoveries to improved outcomes for high risk acute leukemia | API | |
| K22CA216318 K22FY2017–2019$583k | Systems Biology of RAS and RAF Oncogenes and Personalized Medicine | API | |
| P30CA014195 P30FY1985–2026$181.1M | Mass Spectrometry Core (MASS) | API | |
| T32CA009370 T32FY1986–2026$11.0M | Cancer Heterogeneity, Immunity, and Microenvironment (CHIME) Training Program | API | |
| F32CA254140 F32FY2020–2022$152k | Role of WT1 in mixed phenotype acute leukemia | API | |
| K08CA286762 K08FY2024–2026$746k | Calming the Cytokine Storm: Unraveling the Biology of CRS and ICANS | API | |
| K12CA076931 K12FY1997–2026$17.6M | Physician Scientist Training in Clinical Oncology | API | |
| K99CA279756 K99FY2023–2024$272k | Role of BCL11B in lineage ambiguous leukemia | API | |
| R01CA193776 R01FY2015–2026$6.2M | Improving risk allocation and developing novel therapies for children with T-ALL and T-LL | API | |
| R01CA264837 R01FY2021–2025$3.0M | Biomarkers of dasatinib response and resistance in T-cell acute lymphoblastic leukemia | API | |
| R03CA256550 R03FY2021$382k | Genomic Profiling of T-cell Acute Lymphoblastic Leukemia in Children | API | |
| T32CA009615 T32FY1988–2026$12.7M | Cancer Center Research Training Program | API | |
| U24CA196173 U24FY2015–2026$57.5M | COG U24 Funding 2026-2027 | API | |
| U54CA243124 U54FY2019–2023$20.9M | Experimental and preclinical modeling of NUP98-rearranged acute leukemia | API | |
| P30CA021765 P30FY1985–2026$336.4M | Cancer Biology (CBP) | API | |
| U24CA114766 U24FY2005–2014$14.5M | Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) | API | |
| T32CA236748 T32FY2019–2026$2.0M | Childhood Hematological Malignancies Training Program | API | |
| R01CA204396 R01FY2016–2025$5.2M | ABERRANT SIGNALING IN ACUTE MYELOID LEUKEMIA | API | |
| U10CA098413 U10FY2003–2013$67.5M | Children's Oncology Group Statistics and Data Center Grant | API | |
| U10CA180886 U10FY2014–2026$437.3M | COG NCTN Network Group Operations Center | API | |
| U10CA180899 U10FY2014–2026$165.4M | Children's Oncology Group Statistics and Data Center | API | |
| R01CA114563 R01FY2005–2016$4.4M | Biology and Prognostic Implications of FLT3 Mutations in AML | API | |
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API | |
| K08CA256489 K08FY2021–2025$1.2M | Co-targeting BET Bromodomain Proteins and Aberrant Signaling in AML. | API | |
| P30CA008748 P30FY1985–2026$718.7M | Antitumor Assessment | API | |
| P30CA016042 P30FY1985–2026$275.9M | Epigenomics, RNA, and Gene Regulation (ERGR) | API | |
| P30CA016672 P30FY1985–2025$531.6M | Cancer Center Support Grant | API | |
| R01CA180279 R01FY2014–2018$1.8M | 3D Model of Human Ewing Sarcoma | API |
Awards that maintain or redistribute this data
Resource and center grants credited on articles that used the data. Kept out of the flow above because they pay for the pipes, not for a cohort or a finding.
| Award | Project | Evidence |
|---|---|---|
| P30CA008748 P30FY1985–2026$718.7M | Antitumor Assessment | API |
| P30CA014195 P30FY1985–2026$181.1M | Mass Spectrometry Core (MASS) | API |
| P30CA016042 P30FY1985–2026$275.9M | Epigenomics, RNA, and Gene Regulation (ERGR) | API |
| P30CA016672 P30FY1985–2025$531.6M | Cancer Center Support Grant | API |
| P30CA021765 P30FY1985–2026$336.4M | Cancer Biology (CBP) | API |
| U10CA098413 U10FY2003–2013$67.5M | Children's Oncology Group Statistics and Data Center Grant | API |
| U10CA098543 U10FY2003–2013$335.5M | Children's Oncology Group Chair's Grant | API |
| U10CA180886 U10FY2014–2026$437.3M | COG NCTN Network Group Operations Center | API |
| U10CA180899 U10FY2014–2026$165.4M | Children's Oncology Group Statistics and Data Center | API |
| U24CA114766 U24FY2005–2014$14.5M | Support for Human Specimen Banking in NCI-Sponsored Clinical Trials-(CGB) | API |
| U24CA196173 U24FY2015–2026$57.5M | COG U24 Funding 2026-2027 | API |
| U54CA243124 U54FY2019–2023$20.9M | Experimental and preclinical modeling of NUP98-rearranged acute leukemia | API |
Where the links come from
NIH RePORTER maps a PMID to the awards that reported it. On a dataset’s marker paper that gives the awards which created it; on an article that used the data, the awards which funded that use.
The two sides are not measured alike. Generation is complete: a dataset has one marker paper and every award on it is resolved. Reuse is a sample - the articles using a dataset can number in the thousands, and only the few dozen strongest are retrieved and looked up. Every award shown here funded reuse; there are more that are not shown.
How far it reaches
283 datasets have an award credited with creating them, 80 with using them, and 31 both.
What is missing
No citable accession means no traceable articles; no authoritative marker paper means no attributable generation award. Absence is a gap in the record. Methods.
Start from an award instead, and see every dataset it touches.